BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 13, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» INCB-123667 shows efficacy in cyclin E-overexpressing tumor xenograft models
To read the full story,
subscribe
or
sign in
.
Cancer
INCB-123667 shows efficacy in cyclin E-overexpressing tumor xenograft models
Nov. 10, 2022
No Comments
Researchers from Incyte Research Institute presented the discovery of a cyclin-dependent kinase 2 (CDK2) inhibitor, INCB-123667, being developed for the treatment of cyclin E dysregulated cancers.
BioWorld Science
Conferences
Cancer